The efficacy of procalcitonin as a biomarker in the management of sepsis: Slaying dragons or tilting at windmills?

Surgical Infections

Volumn 14, Issue 6, 2013, Pages 489-511

  Sridharan, Prasanna ^a   Chamberlain, Ronald S ^a,b,c  

^a SAINT BARNABAS MEDICAL CENTER   (United States)

^b University of Medicine and Dentistry of New Jersey   (United States)

^c St George's University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BIOLOGICAL MARKER; PROCALCITONIN;

ADULT DISEASE; ANTIBIOTIC THERAPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DRUG DOSE ESCALATION; HUMAN; META ANALYSIS (TOPIC); MULTIPLE ORGAN FAILURE; PARATHYROID HORMONE BLOOD LEVEL; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SENSITIVITY AND SPECIFICITY; SEPSIS; SYSTEMATIC REVIEW;

BIOLOGICAL MARKERS; CALCITONIN; DIAGNOSTIC TESTS, ROUTINE; DRUG MONITORING; HUMANS; PROTEIN PRECURSORS; SEPSIS;

EID: 84892964775     PISSN: 10962964     EISSN: 15578674     Source Type: Journal    
DOI: 10.1089/sur.2012.028     Document Type: Review

References (86)

1. Martin G, Mannino D, Eaton S, et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546-1554
2. Bone R, Balk R, Cerra F, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101: 1644-1655
3. Levy M, Fink M, Marshall J, et al. 2001 SCCM/ESICM/ ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31:1250-1256
4. Agency for Healthcare Research and Quality. HCUP facts and figures: Statistics on hospital-based care in the United States, 2008. Available from: Http://www.hcup-us.ahrq.gov/reports/factsandfigures/2008/TOC-2008.jsp
5. Hall M, Williams S, DeFrances C, et al. Inpatient care for septicemia or sepsis: A challenge for patients and hospitals. NCHS Data Brief 2011; 62. Available from: Www.cdc.gov/ nchs/data/databriefs/db62.pdf
6. Carrigan S, Scott G, Tabrizian M. Toward resolving the challenges of sepsis diagnosis. Clin Chem 2004;50:1301-1314
7. Levy M. The challenge of sepsis. Crit Care 2004;8:435-436
8. Giamarellos-Bourboulis E, Grecka A, Scarpa N, et al. Procalcitonin: A marker to clearly differentiate systemic inflammatory response syndrome and sepsis in the critically ill patient? Intensive Care Med 2002;28:1351-1356
9. Harbarth S, Holeckova K, Froidevaux C, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001;164:396-402
10. Uzzan B, Cohen R, Nicolas P, et al. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: A systematic review and meta-Analysis. Crit Care Med 2006; 34:1996-2003
11. Rivers E, McIntyre L, Morro D, et al. Early and innovative interventions for severe sepsis and septic shock: Taking advantage of a window of opportunity. CMAJ 2005;173: 1054-1065
12. Pierrakos C, Vincent J. Sepsis biomarkers: A review. Crit Care 2010;14:R15
13. Bozza F, Bozza P, Neto H. Beyond sepsis pathophysiology with cytokines: What is their value as biomarkers for disease severity? Mem Inst Oswaldo Cruz 2005;100(Suppl I):217-221
14. Ivady B, Beres B, Szabo D. Recent advances in sepsis research: Novel biomarkers and therapeutic targets. Curr Med Chem 2011;18:3211-3225
15. Gonsalves M, Sakr Y. Early identification of sepsis. Curr Infect Dis Rep 2010;12:329-335
16. Wolff M, Bouadma L. What procalcitonin brings to management of sepsis in the ICU. Crit Care 2010;14:1007
17. Wanner G, Keel M, Steckholzer U, et al. Relationship between procalcitonin plasma levels and severity of injury, sepsis, organ failure, and mortality in injured patients. Crit Care Med 2000; 28:950-957
18. Brunkhorst F, Wegscheider K, Forycki Z, et al. Procalcitonin for early diagnosis and differentiation of SIRS, sepsis, severe sepsis, and septic shock. Intensive Care Med 2000; 26(Suppl 2):S148-152
19. Balci C, Sungurtekin H, Gürses E, et al. Usefulness of procalcitonin for diagnosis of sepsis in the intensive care unit. Crit Care 2000;7:85-90
20. Luzzani A, Polati E, Dorizzi R, et al. Comparison of procalcitonin and C-reactive protein as markers of sepsis. Crit Care Med 2003;31:1737-1741
21. Endo S, Aikawa N, Fujishima S, et al. Usefulness of procalcitonin serum level for the discrimination of severe sepsis from sepsis: A multicenter prospective study. J Infect Chemother 2008;14:244-249
22. Tsangaris I, Plachouras D, Kavatha D, et al. Diagnostic and prognostic value of procalcitonin among febrile critically ill patients with prolonged ICU stay. BMC Infect Dis 2009;9:213
23. Meynaar I, Droog W, Batstra M, Vreeded R, Herbrink P. In critically ill patients, serum procalcitonin is more useful in differentiating between sepsis and SIRS than CRP, Il-6, or LBP. Crit Care Res Pract 2011;2011:594-645
24. Ugarte H, Silva E, Mercan D, et al. Procalcitonin used as a marker of infection in the intensive care unit. Crit Care Med 1999;27:498-504
25. Suprin E, Camus C, Gacouin A, et al. Procalcitonin: A valuable indicator of infection in a medical ICU Intensive Care Med 2000;26:1232-1238
26. Gaïni S, Koldkjær O, Pedersen C, et al. Procalcitonin, lipopolysaccharide-binding protein, interleukin-6 and C-reactive protein in community-Acquired infections and sepsis: A prospective study. Crit Care 2006;10:R53
27. Sudhir U, Venkatachalaiah R, Kumar T, et al. Significance of serum procalcitonin in sepsis. Indian J Crit Care Med 2011; 15:1-5
28. Müller B, Becker K, Schächinger H, et al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med 2000;28:977-983
29. Selberg O, Hecker H, Martin M, et al. Discrimination of sepsis and systemic inflammatory response syndrome by determination of circulating plasma concentrations of procalcitonin, protein complement 3a, and interleukin-6. Crit Care Med 2000;28:2793-2798
30. Castelli G, Pognani C, Meisner M, et al. Procalcitonin and C-reactive protein during systemic inflammatory response syndrome, sepsis and organ dysfunction. Crit Care 2004;8: R234-242
31. Reith H, Mittelkötter U, Wagner R, et al. Procalcitonin (PCT) in patients with abdominal sepsis. Intensive Care Med 2000;26(Suppl 2):S165-169
32. Dorge H, Schondube F, Dorge P, et al. Procalcitonin is a valuable marker in cardiac surgery but not specific for infection. Thorac Cardiovasc Surg 2003;51:322-326
33. Al-Nawas B, Krammer I, Shah P. Procalcitonin in diagnosis of severe infections. Eur J Med Res 1996;1:331-33
34. De Werra I, Jaccard C, Betz Corradin S, et al. Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentrations: Comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia. Crit Care Med 1997;25:607-613
35. Benoist J, Mimoz O, Assicot M, et al. Serum procalcitonin, but not C-reactive protein, identifies sepsis in trauma patients. Clin Chem 1998;44:1778-1779
36. Whang K, Steinwald P, White J, et al. Serum calcitonin precursors in sepsis and systemic inflammation. J Clin Endocrinol Metab 1998;83:3296-3301
37. Bossink A, Groeneveld A, Thijs L. Prediction of microbial infection and mortality in medical patients with fever: Plasma procalcitonin, neutrophilic elastase-Alpha-Antitrypsin, and lactoferrin compared with clinical variables. Clin Infect Dis 1999;29:398-407
38. Rothenburger M, Markewitz A, Lenz T, et al. Detection of acute phase response and infection. The role of procalcitonin and C-reactive protein. Clin Chem Lab Med 1999;37:275-279
39. Adamik B, Kubler-Kielb J, Golebiowska B, et al. Effect of sepsis and cardiac surgery with cardiopulmonary bypass on plasma level of nitric oxide metabolites, neopterin, and procalcitonin: Correlation with mortality and postoperative complications. Intensive Care Med 2000;26:1259-1267
40. Aouifi A, Piriou V, Bastien O, et al. Usefulness of procalcitonin for diagnosis of infection in cardiac surgical patients. Crit Care Med 2000;28:3171-3176
41. Baykut D, Schulte-Herbruggen J, Krian A. The value of procalcitonin as an infection marker in cardiac surgery. Eur J Med Res 2000;5:530-536
42. Boeken U, Feindt P, Micek M, et al. Procalcitonin (PCT) in cardiac surgery: Diagnostic value in systemic inflammatory response syndrome (SIRS), sepsis and after heart transplantation (HTX). Cardiovasc Surg 2000;8:550-554
43. Cheval C, Timsit J, Garrouste-Orgeas M, et al. Procalcitonin (PCT) is useful in predicting the bacterial origin of an acute circulatory failure in critically ill patients. Intensive Care Med 2000; 26(Suppl. 2):S153-158
44. Oberhoffer M, Russwurm S, Bredle D, et al. Discriminative power of inflammatory markers for prediction of tumor necrosis factor-A and interleukin-6 in ICU patients with systemic inflammatory response syndrome (SIRS) or sepsis at arbitrary time points. Intensive Care Med 2000;26:S170-174
45. Yukioka H, Yoshida G, Kurita S, et al. Plasma procalcitonin in sepsis and organ failure. Ann Acad Med Singapore 2001;30:28-31
46. Baumgarten R, Pequeriaux N, Van Puyenbroek M, et al. Diagnosis of sepsis by procalcitonin. Ned Tijdschr Klin Chem 2002;27:32-35
47. Hausfater P, Garric S, Ayed B, et al. Usefulness of procalcitonin as a marker of systemic infection in emergency department patients: A prospective study. Clin Infect Dis 2002;34:895-901
48. Meisner M, Rauschmayer C, Schmidt J, et al. Early increase of procalcitonin after cardiovascular surgery in patients with postoperative complications. Intensive Care Med 2002;28: 1094-1102
49. Ruokonen E, Ilkka L, Niskanen M, et al. Procalcitonin and neopterin as indicators of infection in critically ill patients. Acta Anaesthesiol Scand 2002;46:398-404
50. Tugrul S, Esen F, Celebi S, et al. Reliability of procalcitonin as a severity marker in critically ill patients with inflammatory response. Anaesth Intensive Care 2002;30:747-754
51. De Talance N, Burlet C, Claudel C. La procalcitonine (PCT) est-elle le marqueur spécifique du choc septique? Immunoanalyse et Biologie Spécialisée 2003;18:120-122
52. Du B, Pan J, Chen D, et al. Serum procalcitonin and interleukin-6 levels may help to differentiate systemic inflammatory response of infectious and non-infectious origin. Chin Med J 2003;116:538-542
53. Geppert A, Steiner A, Delle-Karth G, et al. Usefulness of procalcitonin for diagnosing complicating sepsis in patients with cardiogenic shock. Intensive Care Med 2003;29:1384-1389
54. Hensler T, Sauerland S, Lefering R, et al. The clinical value of procalcitonin and neopterin in predicting sepsis and organ failure after major trauma. Shock 2003;20:420-426
55. Kabir K, Keller H, Grass G, et al. Cytokines and chemokines in serum and urine as early predictors to identify septic patients on intensive care unit. Int J Mol Med 2003;12:565-570
56. Chan Y, Tseng C, Tsay P, et al. Procalcitonin as a marker of bacterial infection in the emergency department: An observational study. Crit Care 2004;8:R12-20
57. Clec'h C, Ferriere F, Karoubi P, et al. Diagnostic and prognostic value of procalcitonin in patients with septic shock. Crit Care Med 2004;32:1166-1169
58. Gibot S, Kolopp-Sarda M, Bene M. Plasma level of a triggering receptor expressed on myeloid cells-1: Its diagnostic accuracy in patients with suspected sepsis. Ann Intern Med 2004;141:9-15
59. Aikawa N, Fujishima S, Endo S, et al. Multicenter prospective study of procalcitonin as an indicator of sepsis. J Infect Chemother 2005;11:152-159
60. Mokart D, Merlin M, Sannini A, et al. Procalcitonin, interleukin 6 and systemic inflammatory response syndrome (SIRS): Early markers of postoperative sepsis after major surgery. Br J Anaesth 2005;94:767-773
61. Charles P, Tinel C, Barbar S, et al. Procalcitonin kinetics within the first days of sepsis: Relationship with the appropriateness of antibiotic therapy and the outcome. Crit Care 2009; 13:R38
62. Karlsson S, Heikkinen M, PettiläV, et al. Predictive value of procalcitonin decrease in patients with severe sepsis: A prospective observational study. Crit Care 2010;14:R205
63. Dahaba A, Hagara B, Fall A, et al. Procalcitonin for early prediction of survival outcome in postoperative critically ill patients with severe sepsis. Br J Anaesth 2006;97:503-508
64. Assicot M, Gendrel D, Carsin H, et al. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993;341:515-518
65. Becker K, Snider R, Nylen E. Procalcitonin assay in systemic inflammation, infection, and sepsis: Clinical utility and limitations. Crit Care Med 2008;36:941-952
66. Reith H, Mittelkötter U, Debus E, et al. Procalcitonin in early detection of postoperative complications. Dig Surg 1998;15: 260-265
67. Castelli G, Pognani C, Cita M, et al. Procalcitonin, C-reactive protein, white blood cells and SOFA score in ICU: Diagnosis and monitoring of sepsis. Minerva Anestesiol 2006;72:69-80
68. Lavrentieva A, Kontakiotis T, Lazaridis L, et al. Inflammatory markers in patients with severe burn injury. What is the best indicator of sepsis? Burns 2007;33:189-194
69. Novotny A, Emmanuel K, Hueser N, et al. Procalcitonin ratio indicates successful surgical treatment of abdominal sepsis. Surgery 2009;145:20-26
70. Jensen J, Hein L, Lundgren B, et al. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: A randomized trial. Crit Care Med 2011;39:2048-2058
71. Jensen J, Lundgren B, Hein L, et al. The Procalcitonin And Survival Study (PASS)-A randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker procalcitonin and pro-Active diagnostic and therapeutic responses to abnormal Procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patients. BMC Infect Dis 2008;8:91
72. Nobre V, Harbarth S, Graf J, et al. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: A randomized trial. Am J Respir Crit Care Med 2008;177:498-505
73. Hochreiter M, Köhler T, Schweiger A, et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: A randomized prospective controlled trial. Crit Care 2009;13:R83
74. Schroeder S, Hochreiter M, Koehler T, et al. Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: Results of a prospective randomized study. Langenbecks Arch Surg 2009;394:221-226
75. Bouadma L, Luyt C, Tubach F, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): A multicentre randomised controlled trial. Lancet 2010;375:463-474
76. Tang B, Eslick G, Craig J, et al. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: Systematic review and meta-Analysis. Lancet Infect Dis 2007;7:210-217
77. Jones A, Fiechtl J, Brown M, et al. Procalcitonin test in the diagnosis of bacteremia: A meta-Analysis. Ann Emerg Med 2007;50:34-41
78. Kopterides P, Siempos I, Tsangaris I, et al. Procalcitoninguided algorithms of antibiotic therapy in the intensive care unit: A systematic review and meta-Analysis of randomized controlled trials. Crit Care Med 2010;38:2229-2241
79. Heyland D, Johnson A, Reynolds S, et al. Procalcitonin for reduced antibiotic exposure in the critical care setting: A systematic review and an economic evaluation. Crit Care Med 2011; 39:1792-1799
80. Schuetz P, Chiappa V, Briel M, et al. Procalcitonin algorithms for antibiotic therapy decisions: A systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med 2011;171:1322-1331
81. Wilke M, Grube R, Bodmann K. The use of a standardized PCT-Algorithm reduces costs in intensive care in septic patients-A DRG-based simulation model. Eur J Med Res 2011;16:543-548
82. Klevens R, Edwards J, Richards C, et al. Estimating health care-Associated infections and deaths in U.S. hospitals, 2002. Public Health Rep 2007;122:160-166
83. Brusselaers N, Vogelaers D, Blot S. The rising problem of antimicrobial resistance in the intensive care unit. Ann Intensive Care 2011;1:47
84. Lavrentieva A, Papadopoulou S, Kioumis J, et al. PCT as a diagnostic and prognostic tool in burn patients. Whether time course has a role in monitoring sepsis treatment. Burns 2012;38:356-363
85. Griffith M, Postelnick M, Scheetz M. Antimicrobial stewardship programs: Methods of operation and suggested outcomes. Expert Rev Anti Infect Ther 2012;10:63-73
86. Bal A, Gould I. Antibiotic stewardship: Overcoming implementation barriers. Curr Opin Infect Dis 2011;24:357-362